The leading vertically integrated multi-state cannabis operator in the U.S. issued a statement last week about a letter it received from the Food and Drug Administration (FDA) addressing the company's CBD product marketing.
Curaleaf's statement said the company has prioritized its commitment to complying with the FDA in all its product marketing. It said the company is dedicated to working with the FDA to address the problems addressed in the letter but noted that ‘nothing in the letter raises any issues concerning the quality and consistency of any Curaleaf product.’
The company is required to respond directly to the FDA within 15 working days of receiving the letter. Curaleaf currently operates in 12 states with 48 dispensaries, 13 cultivation sites and 12 processing sites.
